Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David P. Ryan, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 May 30. PMID: 31145418.
    Citations:    
  2. Wo JY, Plastaras JP, Metz JM, Jiang W, Yeap BY, Drapek LC, Adams J, Baglini C, Ryan DP, Murphy JE, Parikh AR, Allen JN, Clark JW, Blaszkowsky LS, DeLaney TF, Ben-Josef E, Hong TS. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. Int J Radiat Oncol Biol Phys. 2019 May 22. PMID: 31128146.
    Citations:    
  3. Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Oncologist. 2019 Apr 30. PMID: 31040255.
    Citations:    
  4. Ryan DP. The Increasingly Complicated Approach to Rectal Cancer. Oncologist. 2019 Jun; 24(6):728-729. PMID: 30996011.
    Citations:    
  5. Yerramilli D, Drapek L, Nipp RD, Horick N, Moran SMC, Noé B, D'Arpino SM, Mitra D, Hong TS, Ryan DP, Dizon DS, Wo J. Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer. J Gastrointest Cancer. 2019 Apr 13. PMID: 30980294.
    Citations:    
  6. Raldow AC, Chen AB, Russell M, Lee PP, Hong TS, Ryan DP, Cusack JC, Wo JY. Cost-effectiveness of Short-Course Radiation Therapy vs Long-Course Chemoradiation for Locally Advanced Rectal Cancer. JAMA Netw Open. 2019 Apr 05; 2(4):e192249. PMID: 30977859.
    Citations:    
  7. Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, Wo JY, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Nipp RD, Parikh A, Qadan M, Warshaw AL, Hong TS, Lillemoe KD, Ferrone CR. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg. 2019 Apr; 269(4):733-740. PMID: 29227344.
    Citations:    Fields:    
  8. Mitra D, Horick NK, Brackett DG, Mouw KW, Hornick JL, Ferrone S, Hong TS, Mamon H, Clark JW, Parikh AR, Allen JN, Ryan DP, Ting DT, Deshpande V, Wo JY. High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. Oncologist. 2019 Jun; 24(6):e275-e283. PMID: 30755500.
    Citations:    
  9. Patel SA, Edgington SK, Adams J, Morse C, Ryan DP, Hong TS. Novel use of proton beam therapy for neoadjuvant treatment of radiation-associated squamous cell carcinoma of the esophagus. J Gastrointest Oncol. 2019 Feb; 10(1):155-160. PMID: 30788171.
    Citations:    
  10. Irwin KE, Park ER, Fields LE, Corveleyn AE, Greer JA, Perez GK, Callaway CA, Jacobs JM, Nierenberg AA, Temel JS, Ryan DP, Pirl WF. Bridge: Person-Centered Collaborative Care for Patients with Serious Mental Illness and Cancer. Oncologist. 2019 Jan 29. PMID: 30696722.
    Citations:    Fields:    
  11. Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, Allen JN, Blaszkowsky LS, Ryan DP, Ferrone CR, Tanabe KK, Qadan M, Crane CH, Koay EJ, Eyler C, DeLaney TF, Zhu AX, Wo JY, Grassberger C, Hong TS. Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. Int J Radiat Oncol Biol Phys. 2019 Jan 23. PMID: 30684667.
    Citations:    Fields:    
  12. Choi JG, Nipp RD, Tramontano A, Ali A, Zhan T, Pandharipande P, Dowling EC, Ferrone CR, Hong TS, Schrag D, Fernandez-Del Castillo C, Ryan DP, Kong CY, Hur C. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Oncologist. 2018 Dec 17. PMID: 30559125.
    Citations:    Fields:    
  13. Mitra D, Clark JW, Shih HA, Oh KS, Brastianos PK, Wo JY, Strickland MR, Curry WT, Parikh AR, Corcoran RB, Ryan DP, Iafrate AJ, Borger DR, Lennerz JK, Hong TS. Enrichment of HER2 Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. Oncologist. 2019 Feb; 24(2):193-201. PMID: 30373904.
    Citations:    Fields:    
  14. Nipp RD, Ruddy M, Fuh CX, Zangardi ML, Chio C, Kim EB, Li BKM, Long Y, Blouin GC, Lage D, Ryan DP, Greer JA, El-Jawahri A, Temel JS. Pilot Randomized Trial of a Pharmacy Intervention for Older Adults with Cancer. Oncologist. 2019 Feb; 24(2):211-218. PMID: 30341175.
    Citations:    Fields:    
  15. Franses JW, Basar O, Kadayifci A, Yuksel O, Choz M, Kulkarni AS, Tai E, Vo KD, Arora KS, Desai N, Licausi JA, Toner M, Maheswaran S, Haber DA, Ryan DP, Brugge WR, Ting DT. Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms. Oncologist. 2018 Oct; 23(10):1260. PMID: 30315083.
    Citations:    Fields:    
  16. Wong RL, El-Jawahri A, D'Arpino SM, Fuh CX, Johnson PC, Lage DE, Irwin KE, Pirl WF, Traeger L, Cashavelly BJ, Jackson VA, Greer JA, Ryan DP, Hochberg EP, Temel JS, Nipp RD. Use of Antidepressant Medications Moderates the Relationship Between Depressive Symptoms and Hospital Length of Stay in Patients with Advanced Cancer. Oncologist. 2019 Jan; 24(1):117-124. PMID: 30082486.
    Citations:    Fields:    
  17. Yozu M, Johncilla ME, Srivastava A, Ryan DP, Cusack JC, Doyle L, Setia N, Yang M, Lauwers GY, Odze RD, Misdraji J. Histologic and Outcome Study Supports Reclassifying Appendiceal Goblet Cell Carcinoids as Goblet Cell Adenocarcinomas, and Grading and Staging Similarly to Colonic Adenocarcinomas. Am J Surg Pathol. 2018 07; 42(7):898-910. PMID: 29579011.
    Citations:    Fields:    
  18. Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernández-Del Castillo C, Ferrone CR, Hong TS. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Jul 01; 4(7):963-969. PMID: 29800971.
    Citations:    Fields:    
  19. Wo JY, Niemierko A, Ryan DP, Blaszkowsky LS, Clark JW, Kwak EL, Lillemoe KD, Drapek LN, Zhu AX, Allen JN, Faris JE, Murphy JE, Nipp R, Fernandez-Del Castillo C, Ferrone CR, Hong TS. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. Am J Clin Oncol. 2018 07; 41(7):656-661. PMID: 28134673.
    Citations: 2     Fields:    
  20. Patra KC, Kato Y, Mizukami Y, Widholz S, Boukhali M, Revenco I, Grossman EA, Ji F, Sadreyev RI, Liss AS, Screaton RA, Sakamoto K, Ryan DP, Mino-Kenudson M, Castillo CF, Nomura DK, Haas W, Bardeesy N. Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol. 2018 07; 20(7):811-822. PMID: 29941929.
    Citations:    Fields:    
  21. Nipp RD, El-Jawahri A, D'Arpino SM, Chan A, Fuh CX, Johnson PC, Lage DE, Wong RL, Pirl WF, Traeger L, Cashavelly BJ, Jackson VA, Ryan DP, Hochberg EP, Temel JS, Greer JA. Symptoms of posttraumatic stress disorder among hospitalized patients with cancer. Cancer. 2018 Aug; 124(16):3445-3453. PMID: 29905935.
    Citations:    Fields:    
  22. Hong TS, Ryan DP. Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer-The New Standard of Care? JAMA Oncol. 2018 Jun 14; 4(6):e180070. PMID: 29566113.
    Citations: 1     Fields:    
  23. Keane FK, Wo JY, Ferrone CR, Clark JW, Blaszkowsky LS, Allen JN, Kwak EL, Ryan DP, Lillemoe KD, Fernandez-Del Castillo C, Hong TS. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. Am J Clin Oncol. 2018 06; 41(6):607-612. PMID: 27740973.
    Citations: 2     Fields:    
  24. Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS. Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Med. 2018 May 17. PMID: 29771009.
    Citations: 1     Fields:    
  25. McDuff SGR, Remillard KA, Zheng H, Raldow AC, Wo JY, Eyler CE, Drapek LC, Goyal L, Blaszkowsky LS, Clark JW, Allen JN, Parikh AR, Ryan DP, Ferrone CR, Tanabe KK, Wolfgang JA, Zhu AX, Hong TS. Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Pract Radiat Oncol. 2018 Nov - Dec; 8(6):414-421. PMID: 29937235.
    Citations:    Fields:    Translation:Humans
  26. O'Reilly EM, Roach J, Miller P, Yu KH, Tjan C, Rosano M, Krause S, Avery W, Wolf J, Flaherty K, Nix D, Ryan DP. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. Oncologist. 2017 12; 22(12):1429-e139. PMID: 29158367.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  27. Lage DE, Nipp RD, D'Arpino SM, Moran SM, Johnson PC, Wong RL, Pirl WF, Hochberg EP, Traeger LN, Jackson VA, Cashavelly BJ, Martinson HS, Greer JA, Ryan DP, Temel JS, El-Jawahri A. Predictors of Posthospital Transitions of Care in Patients With Advanced Cancer. J Clin Oncol. 2018 01 01; 36(1):76-82. PMID: 29068784.
    Citations:    Fields:    
  28. Nipp RD, El-Jawahri A, Moran SM, D'Arpino SM, Johnson PC, Lage DE, Wong RL, Pirl WF, Traeger L, Lennes IT, Cashavelly BJ, Jackson VA, Greer JA, Ryan DP, Hochberg EP, Temel JS. The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer. Cancer. 2017 Dec 01; 123(23):4720-4727. PMID: 29057450.
    Citations: 4     Fields:    Translation:Humans
  29. El-Jawahri A, Lau-Min K, Nipp RD, Greer JA, Traeger LN, Moran SM, D'Arpino SM, Hochberg EP, Jackson VA, Cashavelly BJ, Martinson HS, Ryan DP, Temel JS. Processes of code status transitions in hospitalized patients with advanced cancer. Cancer. 2017 Dec 15; 123(24):4895-4902. PMID: 28881383.
    Citations:    Fields:    Translation:Humans
  30. Miller CL, Taylor MS, Qadan M, Deshpande V, Worthington S, Smalley R, Collura C, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Parikh AR, Berger D, Tanabe KK, Lillemoe KD, Ferrone CR. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. J Gastrointest Surg. 2017 Nov; 21(11):1831-1840. PMID: 28884391.
    Citations: 2     Fields:    Translation:Humans
  31. Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Tanguturi S, Goyal L, Murphy JE, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Tanabe KK, Ferrone CR, Ryan DP, Iafrate AJ, DeLaney TF, Zhu AX. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. J Natl Cancer Inst. 2017 09 01; 109(9). PMID: 28954285.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  32. Franses JW, Basar O, Kadayifci A, Yuksel O, Choz M, Kulkarni AS, Tai E, Vo KD, Arora KS, Desai N, Licausi JA, Toner M, Maheswaran S, Haber DA, Ryan DP, Brugge WR, Ting DT. Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms. Oncologist. 2018 01; 23(1):121-127. PMID: 28860411.
    Citations:    Fields:    
  33. Pergolini I, Morales-Oyarvide V, Mino-Kenudson M, Honselmann KC, Rosenbaum MW, Nahar S, Kem M, Ferrone CR, Lillemoe KD, Bardeesy N, Ryan DP, Thayer SP, Warshaw AL, Fernández-Del Castillo C, Liss AS. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. PLoS One. 2017; 12(8):e0182855. PMID: 28854237.
    Citations: 3     Fields:    Translation:HumansAnimals
  34. Kishan AU, Voog JC, Wiseman J, Cook RR, Ancukiewicz M, Lee P, Ryan DP, Clark JW, Berger DL, Cusack JC, Wo JY, Hong TS. Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease. Br J Radiol. 2017 Aug; 90(1076):20170134. PMID: 28613934.
    Citations:    Fields:    Translation:Humans
  35. Liu H, Naxerova K, Pinter M, Incio J, Lee H, Shigeta K, Ho WW, Crain JA, Jacobson A, Michelakos T, Dias-Santos D, Zanconato A, Hong TS, Clark JW, Murphy JE, Ryan DP, Deshpande V, Lillemoe KD, Fernandez-Del Castillo C, Downes M, Evans RM, Michaelson J, Ferrone CR, Boucher Y, Jain RK. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017 Oct 01; 23(19):5959-5969. PMID: 28600474.
    Citations: 8     Fields:    Translation:HumansCells
  36. Nipp RD, Greer JA, El-Jawahri A, Moran SM, Traeger L, Jacobs JM, Jacobsen JC, Gallagher ER, Park ER, Ryan DP, Jackson VA, Pirl WF, Temel JS. Coping and Prognostic Awareness in Patients With Advanced Cancer. J Clin Oncol. 2017 Aug 01; 35(22):2551-2557. PMID: 28574777.
    Citations: 1     Fields:    Translation:Humans
  37. Irwin KE, Park ER, Shin JA, Fields LE, Jacobs JM, Greer JA, Taylor JB, Taghian AG, Freudenreich O, Ryan DP, Pirl WF. Predictors of Disruptions in Breast Cancer Care for Individuals with Schizophrenia. Oncologist. 2017 11; 22(11):1374-1382. PMID: 28559411.
    Citations:    Fields:    Translation:Humans
  38. Rose B, Mitra D, Hong TS, Jee KW, Niemierko A, Drapek LN, Blaszkowsky LS, Allen JN, Murphy JE, Clark JW, Ryan DP, Wo JY. Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation. Pract Radiat Oncol. 2017 Sep - Oct; 7(5):e291-e297. PMID: 28462895.
    Citations:    Fields:    Translation:HumansPHPublic Health
  39. Mitra D, Hong TS, Horick N, Rose B, Drapek LN, Blaszkowsky LS, Allen JN, Kwak EL, Murphy JE, Clark JW, Ryan DP, Cusack JC, Bordeianou LG, Berger DL, Wo JY. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Adv Radiat Oncol. 2017 Apr-Jun; 2(2):110-117. PMID: 28740921.
    Citations: 2     
  40. Nipp RD, Zanconato A, Zheng H, Ferrone CR, Lillemoe KD, Wo JY, Hong TS, Clark JW, Ryan DP, Fernández-Del Castillo C. Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment. Pancreas. 2017 02; 46(2):183-189. PMID: 27846142.
    Citations: 1     Fields:    Translation:Humans
  41. Kalinich M, Bhan I, Kwan TT, Miyamoto DT, Javaid S, LiCausi JA, Milner JD, Hong X, Goyal L, Sil S, Choz M, Ho U, Kapur R, Muzikansky A, Zhang H, Weitz DA, Sequist LV, Ryan DP, Chung RT, Zhu AX, Isselbacher KJ, Ting DT, Toner M, Maheswaran S, Haber DA. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2017 01 31; 114(5):1123-1128. PMID: 28096363.
    Citations: 14     Fields:    Translation:HumansCells
  42. Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, Van Seventer EE, Gurski JM, Baltschukat S, Schacher-Engstler B, Barys L, Stamm C, Furet P, Ryan DP, Stone JR, Iafrate AJ, Getz G, Porta DG, Tiedt R, Bardelli A, Juric D, Corcoran RB, Bardeesy N, Zhu AX. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2017 03; 7(3):252-263. PMID: 28034880.
    Citations: 23     Fields:    Translation:Humans
  43. Temel JS, Greer JA, El-Jawahri A, Pirl WF, Park ER, Jackson VA, Back AL, Kamdar M, Jacobsen J, Chittenden EH, Rinaldi SP, Gallagher ER, Eusebio JR, Li Z, Muzikansky A, Ryan DP. Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial. J Clin Oncol. 2017 Mar 10; 35(8):834-841. PMID: 28029308.
    Citations: 32     Fields:    Translation:Humans
  44. Jackson VA, Greer JA, Pirl WF, Park ER, Back A, Muzikansky A, Kamdar M, Rinaldi S, Jacobsen J, Fishbein J, Eusebio J, VanDusen H, Nipp RD, Ryan DP, Temel JS. Effect of early integrated palliative care on family caregivers (FC) outcomes for patients with gastrointestinal and lung cancer. J Clin Oncol. 2016 Oct 09; 34(26_suppl):234. PMID: 28156551.
    Citations:    
  45. El-Jawahri A, Moran SM, D'Arpino S, Johnson C, Lage DE, Wong R, Xiao Y, VanDusen H, Pirl WF, Traeger L, Lennes IT, Cashavelly BJ, Martinson HS, Jackson VA, Greer JA, Ryan DP, Hochberg EP, Temel JS. Symptom burden to predict health care utilization in hospitalized patients with incurable cancer. J Clin Oncol. 2016 Oct 09; 34(26_suppl):98. PMID: 28156457.
    Citations:    
  46. Ryan DP, Hong TS. Understanding the Paradigm Shift in Pancreatic Cancer. J Oncol Pract. 2016 10; 12(10):926-927. PMID: 27858558.
    Citations:    Fields:    Translation:Humans
  47. Schoenfeld JD, Wo JY, Mamon HJ, Kwak EL, Mullen JT, Enzinger PZ, Blaskowsky LS, Ryan DP, Hong TS. The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation. Am J Clin Oncol. 2016 06; 39(3):243-7. PMID: 24577163.
    Citations: 1     Fields:    Translation:Humans
  48. Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, Jung J, Wyant T, Fasanmade AA, Messersmith W, Rodon J. Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies. Clin Cancer Res. 2016 Oct 15; 22(20):5049-5057. PMID: 27178743.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  49. Patel SA, Ryan DP, Hong TS. Combined Modality Therapy for Rectal Cancer. Cancer J. 2016 May-Jun; 22(3):211-7. PMID: 27341601.
    Citations: 1     Fields:    Translation:Humans
  50. Lennes IT, Bohlen N, Park ER, Mort E, Burke D, Ryan DP. Chemotherapy Errors: A Call for a Standardized Approach to Measurement and Reporting. J Oncol Pract. 2016 Apr; 12(4):e495-501. PMID: 26957639.
    Citations:    Fields:    Translation:Humans
  51. Muralidhar V, Nipp RD, Ryan DP, Hong TS, Nguyen PL, Wo JY. Association Between Very Small Tumor Size and Increased Cancer-Specific Mortality in Node-Positive Colon Cancer. Dis Colon Rectum. 2016 Mar; 59(3):187-93. PMID: 26855392.
    Citations: 1     Fields:    Translation:Humans
  52. Eusebio J, Bohlen N, Ruddy M, Ryan DP. Characterization of unplanned 30-day medical oncology readmissions after discharge at an academic medical center with a comprehensive cancer center. J Clin Oncol. 2016 Mar; 34(7_suppl):269. PMID: 28152889.
    Citations:    
  53. Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8. PMID: 26668346.
    Citations: 34     Fields:    Translation:HumansCTClinical Trials
  54. El-Jawahri A, Pirl WF, Traeger L, Kumar P, Ryan DP, Lennes IT, Cashavelly BJ, Martinson HS, VanDusen H, Hochberg EP, Jackson VA, Greer JA, Temel JS, Nipp RD. Symptom burden in hospitalized patients with advanced cancer. J Clin Oncol. 2015 Oct 10; 33(29_suppl):100. PMID: 28148090.
    Citations:    
  55. Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Borger DR, Godfrey JT, Jessop NA, Clark JW, Blaszkowsky LS, Ryan DP, Lennerz JK, Iafrate AJ, Bardelli A, Hong TS, Corcoran RB. Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. Cancer Discov. 2015 12; 5(12):1271-81. PMID: 26432108.
    Citations: 26     Fields:    Translation:Humans
  56. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015 Dec 01; 33(34):4023-31. PMID: 26392102.
    Citations: 71     Fields:    Translation:HumansAnimalsCTClinical Trials
  57. Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst. 2015 Nov; 107(11). PMID: 26374429.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  58. Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist. 2015 Sep; 20(9):1019-27. PMID: 26245674.
    Citations: 12     Fields:    Translation:Humans
  59. Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D. Rectal Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun; 13(6):719-28; quiz 728. PMID: 26085388.
    Citations: 33     Fields:    Translation:Humans
  60. Nipp RD, Ryan DP. Predicting a response to FOLFIRINOX in pancreatic cancer. J Natl Cancer Inst. 2015 Aug; 107(8). PMID: 26025325.
    Citations:    Fields:    Translation:Humans
  61. Hong TS, Ryan DP. Adjuvant Chemotherapy for Locally Advanced Rectal Cancer: Is It a Given? J Clin Oncol. 2015 Jun 10; 33(17):1878-80. PMID: 25940719.
    Citations: 3     Fields:    Translation:HumansCells
  62. Nipp RD, Ryan DP. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer? Oncologist. 2015 Mar; 20(3):236-8. PMID: 25660156.
    Citations: 2     Fields:    Translation:Humans
  63. Chan CH, Cusack JC, Ryan DP. A critical look at local-regional management of peritoneal metastasis. Hematol Oncol Clin North Am. 2015 Feb; 29(1):153-8. PMID: 25475577.
    Citations: 2     Fields:    Translation:Humans
  64. Percac-Lima S, Cronin PR, Ryan DP, Chabner BA, Daly EA, Kimball AB. Patient navigation based on predictive modeling decreases no-show rates in cancer care. Cancer. 2015 May 15; 121(10):1662-70. PMID: 25585595.
    Citations: 5     Fields:    Translation:Humans
  65. Cercek A, Cusack JC, Ryan DP. Treatment of peritoneal carcinomatosis of colorectal origin. Am Soc Clin Oncol Educ Book. 2015; e208-11. PMID: 25993175.
    Citations: 1     Fields:    Translation:Humans
  66. Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015 Jan; 261(1):12-7. PMID: 25599322.
    Citations: 65     Fields:    Translation:Humans
  67. Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J, Chiorean EG, Rosen PJ, Ulrich B, Dragovich T, Del Prete SA, Rarick M, Eng C, Kroll S, Ryan DP. Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. J Clin Oncol. 2015 May 01; 33(13):1475-81. PMID: 25512461.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  68. Goldman J, Eckhardt SG, Borad MJ, Curtis KK, Hidalgo M, Calvo E, Ryan DP, Wirth LJ, Parikh A, Partyka J, Faessel H, Gangolli E, Stewart S, Rosen LS, Bowles DW. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 01; 21(5):1002-9. PMID: 25501576.
    Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
  69. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014 11 27; 371(22):2140-1. PMID: 25427123.
    Citations: 80     Fields:    Translation:Humans
  70. Mirabeau-Beale K, Hong TS, Niemierko A, Ancukiewicz M, Blaszkowsky LS, Crowley EM, Cusack JC, Drapek LC, Kovalchuk N, Markowski M, Napolitano B, Nyamwanda J, Ryan DP, Wolfgang J, Kachnic LA, Wo JY. Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer. Pract Radiat Oncol. 2015 May-Jun; 5(3):e113-8. PMID: 25424587.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  71. Rostamnjad L, Diviak M, Ryan DP, Blouin GC. Justification of more expensive antiemetic use with FOLFOX at an ambulatory cancer center. J Clin Oncol. 2014 Oct 20; 32(30_suppl):27. PMID: 28141436.
    Citations:    
  72. Zenteno Langle AC, Duk M, Levy Carlis A, Bloom M, Souza E, Levi R, Ryan DP. Modeling and improving chemotherapy patient flow. J Clin Oncol. 2014 Oct 20; 32(30_suppl):175. PMID: 28141203.
    Citations:    
  73. Bohlen N, Ryan DP. Improving safety culture at a large AMC. J Clin Oncol. 2014 Oct 20; 32(30_suppl):105. PMID: 28141396.
    Citations:    
  74. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014 Sep 11; 371(11):1039-49. PMID: 25207767.
    Citations: 286     Fields:    Translation:Humans
  75. Abtahian F, Hawkins BM, Ryan DP, Cefalo P, Nasser NJ, MacKay C, Jaff MR, Weinberg I. Inferior vena cava filter usage, complications, and retrieval rate in cancer patients. Am J Med. 2014 Nov; 127(11):1111-7. PMID: 24997415.
    Citations: 9     Fields:    Translation:Humans
  76. Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA. Colon cancer, version 3.2014. J Natl Compr Canc Netw. 2014 Jul; 12(7):1028-59. PMID: 24994923.
    Citations: 65     Fields:    Translation:Humans
  77. Ting DT, Ryan DP. The wide gulf between stage III and stage IV colon cancer. Lancet Oncol. 2014 Jul; 15(8):785-6. PMID: 24928084.
    Citations:    Fields:    Translation:Humans
  78. Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-del Castillo C, Duda DG. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):830-8. PMID: 24867540.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  79. O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori GS, Eakle J, Robertson JM, Moore DF, Mullane MR, Marchello BT, Ward PJ, Wozniak TF, Roh MS, Yothers G, Wolmark N. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014 Jun 20; 32(18):1927-34. PMID: 24799484.
    Citations: 64     Fields:    Translation:Humans
  80. Schapira L, Blaszkowsky LS, Cashavelly BJ, Kim CY, Riley JP, Wold MC, Ryan DP, Penson RT. Caring for one of our own. Oncologist. 2014 May; 19(5):545-9. PMID: 24721818.
    Citations: 3     Fields:    Translation:Humans
  81. Russo AL, Ryan DP, Borger DR, Wo JY, Szymonifka J, Liang WY, Kwak EL, Blaszkowsky LS, Clark JW, Allen JN, Zhu AX, Berger DL, Cusack JC, Mamon HJ, Haigis KM, Hong TS. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. J Gastrointest Cancer. 2014 Mar; 45(1):34-9. PMID: 24006244.
    Citations: 9     Fields:    Translation:Humans
  82. Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer. 2014 May 15; 120(10):1482-90. PMID: 24500602.
    Citations: 19     Fields:    Translation:Humans
  83. Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, Blaszkowsky LS, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Bardeesy N, Straley KS, Agresta S, Schenkein DP, Ellisen LW, Ryan DP, Zhu AX. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1884-90. PMID: 24478380.
    Citations: 26     Fields:    Translation:Humans
  84. Goyal L, Supko JG, Berlin J, Blaszkowsky LS, Carpenter A, Heuman DM, Hilderbrand SL, Stuart KE, Cotler S, Senzer NN, Chan E, Berg CL, Clark JW, Hezel AF, Ryan DP, Zhu AX. Phase 1 study of N(1),N(11)-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1305-14. PMID: 24121453.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  85. Hong TS, DeLaney TF, Mamon HJ, Willett CG, Yeap BY, Niemierko A, Wolfgang JA, Lu HM, Adams J, Weyman EA, Arellano RS, Blaszkowsky LS, Allen JN, Tanabe KK, Ryan DP, Zhu AX. A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):316-322. PMID: 25194100.
    Citations: 9     Fields:    Translation:Humans
  86. Wo JY, Mamon HJ, Ferrone CR, Ryan DP, Blaszkowsky LS, Kwak EL, Tseng YD, Napolitano BN, Ancukiewicz M, Swanson RS, Lillemoe KD, Fernandez-del Castillo C, Hong TS. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Radiother Oncol. 2014 Jan; 110(1):160-4. PMID: 24231241.
    Citations: 6     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  87. Chio C, Kim EB, Ryan DP. Evaluating adherence to off-label policy at an academic outpatient cancer center and assessing reimbursement of high-cost drugs. J Clin Oncol. 2013 Nov; 31(31_suppl):61. PMID: 28136485.
    Citations:    
  88. Bohlen N, Rosato E, Fitzgerald E, Cashavelly BJ, Lafleur K, Ahmed S, Burke D, Ryan DP. Chemotherapy order review, activation, preparation, and administration redesign at a large academic cancer center. J Clin Oncol. 2013 Nov; 31(31_suppl):221. PMID: 28136345.
    Citations:    
  89. Mullen JT, Ryan DP. Neoadjuvant chemotherapy for gastric cancer: what are we trying to accomplish? Ann Surg Oncol. 2014 Jan; 21(1):13-5. PMID: 24046112.
    Citations: 5     Fields:    Translation:Humans
  90. Cai S, Hong TS, Goldberg SI, Fernandez-del Castillo C, Thayer SP, Ferrone CR, Ryan DP, Blaszkowsky LS, Kwak EL, Willett CG, Lillemoe KD, Warshaw AL, Wo JY. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. Cancer. 2013 Dec 01; 119(23):4196-204. PMID: 24006012.
    Citations: 13     Fields:    Translation:Humans
  91. Faris JE, Ryan DP. Controversy and consensus on the management of patients with pseudomyxoma peritonei. Curr Treat Options Oncol. 2013 Sep; 14(3):365-73. PMID: 23934509.
    Citations: 3     Fields:    Translation:Humans
  92. Wo JY, Childs SK, Szymonifka J, Mamon HJ, Ryan DP, Blaszkowsky LS, Kwak EL, Ferrone CR, Allen JN, Zhu AX, Wolpin BM, Chan JA, Abrams TA, McCleary NJ, Fernandez-Del Castillo C, Hong TS. Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):e117-e123. PMID: 24890357.
    Citations: 1     Fields:    Translation:Humans
  93. Ng K, Tabernero J, Hwang J, Bajetta E, Sharma S, Del Prete SA, Arrowsmith ER, Ryan DP, Sedova M, Jin J, Malek K, Fuchs CS. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Clin Cancer Res. 2013 Jul 15; 19(14):3987-95. PMID: 23743569.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  94. Chan JA, Blaszkowsky L, Stuart K, Zhu AX, Allen J, Wadlow R, Ryan DP, Meyerhardt J, Gonzalez M, Regan E, Zheng H, Kulke MH. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer. 2013 Sep 01; 119(17):3212-8. PMID: 23733618.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  95. Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013; 18(5):543-8. PMID: 23657686.
    Citations: 68     Fields:    Translation:Humans
  96. Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA. Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 May 01; 11(5):519-28. PMID: 23667203.
    Citations: 29     Fields:    Translation:Humans
  97. Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D, Rose J, Bekaii-Saab T, Chen HX, Fuchs CS, Ng K. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs. 2014 Feb; 32(1):113-22. PMID: 23568716.
    Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
  98. Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Castillo CF, Deshpande V, Hong TS, Kwak EL, Lauwers GY, Ryan DP, Wargo JA, Lillemoe KD, Ferrone CR. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg. 2013 Apr; 257(4):731-6. PMID: 22968073.
    Citations: 68     Fields:    Translation:Humans
  99. Lee MS, Mamon HJ, Hong TS, Choi NC, Fidias PM, Kwak EL, Meyerhardt JA, Ryan DP, Bueno R, Donahue DM, Jaklitsch MT, Lanuti M, Rattner DW, Fuchs CS, Enzinger PC. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist. 2013; 18(3):281-7. PMID: 23429739.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  100. Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 Feb 01; 11(2):141-52; quiz 152. PMID: 23411381.
    Citations: 42     Fields:    Translation:Humans
  101. Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013 Mar 15; 19(6):1557-66. PMID: 23362324.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  102. Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fuchs CS, Grem JL, Hunt S, Leong LA, Lin E, Martin MG, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Freedman-Cass DA, Gregory KM. Rectal cancer. J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1528-64. PMID: 23221790.
    Citations: 42     Fields:    Translation:Humans
  103. Phillips JG, Hong TS, Ryan DP. Multidisciplinary management of early-stage rectal cancer. J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1577-85. PMID: 23221792.
    Citations: 1     Fields:    Translation:Humans
  104. Chin JY, Hong TS, Ryan DP. Mitomycin in anal cancer: still the standard of care. J Clin Oncol. 2012 Dec 10; 30(35):4297-301. PMID: 23150704.
    Citations: 3     Fields:    Translation:Humans
  105. McCleary NJ, Odejide O, Szymonifka J, Ryan D, Hezel A, Meyerhardt JA. Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer. Clin Colorectal Cancer. 2013 Mar; 12(1):62-9. PMID: 23102897.
    Citations: 6     Fields:    Translation:Humans
  106. Chan JA, Ryan DP, Zhu AX, Abrams TA, Wolpin BM, Malinowski P, Regan EM, Fuchs CS, Kulke MH. Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr Relat Cancer. 2012 Oct; 19(5):615-23. PMID: 22736724.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  107. Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol. 2012 Aug; 13(8):e362-9. PMID: 22846841.
    Citations: 24     Fields:    Translation:Humans
  108. Ryan DP. A partnership between the academic and the community. J Natl Compr Canc Netw. 2012 Aug; 10(8):919-21. PMID: 22878815.
    Citations:    Fields:    Translation:Humans
  109. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, Sequist LV, Bardeesy N, Ramaswamy S, Toner M, Maheswaran S, Haber DA. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012 Jul 26; 487(7408):510-3. PMID: 22763454.
    Citations: 160     Fields:    Translation:HumansAnimalsCells
  110. Benson AB, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fakih MG, Fleshman JW, Fuchs CS, Grem JL, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett C, Freedman-Cass DA. Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Apr; 10(4):449-54. PMID: 22491045.
    Citations: 17     Fields:    Translation:Humans
  111. Chen RC, Mamon HJ, Ancukiewicz M, Killoran JH, Crowley EM, Blaszkowsky LS, Wo JY, Ryan DP, Hong TS. Dose--volume effects on patient-reported acute gastrointestinal symptoms during chemoradiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):e513-7. PMID: 22436781.
    Citations: 7     Fields:    Translation:Humans
  112. Arvold ND, Willett CG, Fernandez-del Castillo C, Ryan DP, Ferrone CR, Clark JW, Blaszkowsky LS, Deshpande V, Niemierko A, Allen JN, Kwak EL, Wadlow RC, Zhu AX, Warshaw AL, Hong TS. Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e337-43. PMID: 22414286.
    Citations: 5     Fields:    Translation:Humans
  113. Faris JE, Ryan DP. Trees, forests, and other implications of a BRAF mutant gene signature in patients with BRAF wild-type disease. J Clin Oncol. 2012 Apr 20; 30(12):1255-7. PMID: 22393091.
    Citations: 2     Fields:    Translation:Humans
  114. Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, Borger DR, Bhan AK, Hoang MP, Iafrate AJ, Cusack JC, Engelman JA, Dias-Santagata D. Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res. 2012 Mar 01; 18(5):1227-36. PMID: 22261808.
    Citations: 29     Fields:    Translation:HumansCells
  115. Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist. 2012; 17(1):14. PMID: 22210091.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  116. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012; 17(1):72-9. PMID: 22180306.
    Citations: 157     Fields:    Translation:Humans
  117. Benson AB, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fleshman JW, Fuchs CS, Grem JL, Knol JA, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett C. Colon cancer. J Natl Compr Canc Netw. 2011 Nov; 9(11):1238-90. PMID: 22056656.
    Citations: 12     Fields:    Translation:Humans
  118. Arvold ND, Ryan DP, Niemierko A, Blaszkowsky LS, Kwak EL, Wo JY, Allen JN, Clark JW, Wadlow RC, Zhu AX, Fernandez-Del Castillo C, Hong TS. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer. 2012 Jun 15; 118(12):3026-35. PMID: 22020923.
    Citations: 22     Fields:    Translation:Humans
  119. Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest. 2011 Nov; 121(11):4311-21. PMID: 21985784.
    Citations: 73     Fields:    Translation:HumansAnimalsCells
  120. Faris JE, Arnott J, Zheng H, Ryan DP, Abrams TA, Blaszkowsky LS, Clark JW, Enzinger PC, Hezel AF, Ng K, Wolpin BM, Kwak EL. A phase 2 study of oral MKC-1, an inhibitor of importin-ß, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012 Aug; 30(4):1614-20. PMID: 21800081.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  121. Wo JY, Mamon HJ, Ryan DP, Hong TS. T3N0 rectal cancer: radiation for all? Semin Radiat Oncol. 2011 Jul; 21(3):212-9. PMID: 21645866.
    Citations: 8     Fields:    Translation:Humans
  122. Alexander BM, Fernandez-Del Castillo C, Ryan DP, Kachnic LA, Hezel AF, Niemierko A, Willett CG, Kozak KR, Blaszkowsky LS, Clark JW, Warshaw AL, Hong TS. Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy. Gastrointest Cancer Res. 2011 Jul; 4(4):116-21. PMID: 22368734.
    Citations: 5     
  123. Wo JY, Ryan DP, Kulke MH, Hong TS. Radiation recall associated with insulin growth factor 1R antibody. Pract Radiat Oncol. 2011 Jul-Sep; 1(3):208-11. PMID: 24673952.
    Citations:    Fields:    
  124. Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011 Nov 15; 117(22):5094-102. PMID: 21538343.
    Citations: 65     Fields:    Translation:HumansCTClinical Trials
  125. Margalit DN, Mamon HJ, Ancukiewicz M, Kobayashi W, Ryan DP, Blaszkowsky LS, Clark J, Willett CG, Hong TS. Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):e735-41. PMID: 21377289.
    Citations: 14     Fields:    Translation:Humans
  126. Kozyreva ON, Chi D, Clark JW, Wang H, Theall KP, Ryan DP, Zhu AX. A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma. Oncologist. 2011; 16(3):310-8. PMID: 21349948.
    Citations: 8     Fields:    Translation:Humans
  127. Goldberg RM, Ryan DP. Scan? Cure? Sure! Oncologist. 2011; 16(2):254-6. PMID: 21349952.
    Citations:    Fields:    Translation:Humans
  128. Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, Willins JD, Ryan DP, Hong TS. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):153-8. PMID: 21095071.
    Citations: 37     Fields:    Translation:Humans
  129. Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP, Jain RK. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value. Clin Cancer Res. 2011 Feb 15; 17(4):918-27. PMID: 20843836.
    Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
  130. Murphy JE, Ryan DP. American Society of Clinical Oncology 2010 colorectal update. Expert Rev Anticancer Ther. 2010 Sep; 10(9):1371-3. PMID: 20836671.
    Citations: 8     Fields:    Translation:Humans
  131. Wadlow RC, Ryan DP. The role of targeted agents in preoperative chemoradiation for rectal cancer. Cancer. 2010 Aug 01; 116(15):3537-48. PMID: 20564106.
    Citations: 8     Fields:    Translation:Humans
  132. Ryan DP, Engelman JA, Ferrone CR, Sahani DV, Lisovsky M. Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum. N Engl J Med. 2010 Jun 24; 362(25):2411-9. PMID: 20573930.
    Citations:    Fields:    Translation:Humans
  133. Hong TS, Ryan DP, Blaszkowsky LS, Mamon HJ, Kwak EL, Mino-Kenudson M, Adams J, Yeap B, Winrich B, DeLaney TF, Fernandez-Del Castillo C. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Int J Radiat Oncol Biol Phys. 2011 Jan 01; 79(1):151-7. PMID: 20421151.
    Citations: 18     Fields:    Translation:HumansCTClinical Trials
  134. Engstrom PF, Arnoletti JP, Benson AB, Berlin JD, Berry JM, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Knol JA, Leong LA, Lin E, Mulcahy MF, Rohren E, Ryan DP, Saltz L, Shibata D, Skibber JM, Small W, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Canc Netw. 2010 Jan; 8(1):106-20. PMID: 20064293.
    Citations: 18     Fields:    Translation:Humans
  135. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010 Jan; 11(1):48-54. PMID: 19932054.
    Citations: 66     Fields:    Translation:HumansCTClinical Trials
  136. Miyamoto DT, Mamon HJ, Ryan DP, Willett CG, Ancukiewicz M, Kobayashi WK, Blaszkowsky L, Fernandez-del Castillo C, Hong TS. Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1171-7. PMID: 19800182.
    Citations: 11     Fields:    Translation:Humans
  137. Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):778-831. PMID: 19755046.
    Citations: 131     Fields:    Translation:Humans
  138. Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):838-81. PMID: 19755047.
    Citations: 110     Fields:    Translation:Humans
  139. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3027-35. PMID: 19470923.
    Citations: 169     Fields:    Translation:HumansCells
  140. Zawacki WJ, Walker TG, DeVasher E, Halpern EF, Waltman AC, Wicky ST, Ryan DP, Kalva SP. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy. J Vasc Interv Radiol. 2009 May; 20(5):624-7; quiz 571. PMID: 19328717.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  141. Goulart BH, Clark JW, Lauwers GY, Ryan DP, Grenon N, Muzikansky A, Zhu AX. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol. 2009 Mar 16; 2:13. PMID: 19291303.
    Citations: 7     Fields:    Translation:Humans
  142. Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009 Jan 01; 15(1):338-45. PMID: 19118063.
    Citations: 77     Fields:    Translation:Humans
  143. Zhu AX, Ready N, Clark JW, Safran H, Amato A, Salem N, Pace S, He X, Zvereva N, Lynch TJ, Ryan DP, Supko JG. Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009 Jan 01; 15(1):374-81. PMID: 19118068.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  144. Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, Fuchs CS. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009 Jan 10; 27(2):193-8. PMID: 19047305.
    Citations: 92     Fields:    Translation:HumansCellsCTClinical Trials
  145. Wright FC, Gagliardi AR, Law CH, Last LD, Klevan AE, Hongjinda S, Stitt LW, Klar N, Ryan DP, Smith AJ. A randomized controlled trial to improve lymph node assessment in stage II colon cancer. Arch Surg. 2008 Nov; 143(11):1050-5; discussion 1055. PMID: 19015462.
    Citations: 7     Fields:    Translation:Humans
  146. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008 Jul 10; 26(20):3403-10. PMID: 18612155.
    Citations: 144     Fields:    Translation:HumansCTClinical Trials
  147. Asomaning K, Reid AE, Zhou W, Heist RS, Zhai R, Su L, Kwak EL, Blaszkowsky L, Zhu AX, Ryan DP, Christiani DC, Liu G. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin Cancer Res. 2008 Jun 15; 14(12):4010-5. PMID: 18559624.
    Citations: 13     Fields:    Translation:HumansCells
  148. Kozuch PS, Rocha-Lima CM, Dragovich T, Hochster H, O'Neil BH, Atiq OT, Pipas JM, Ryan DP, Lenz HJ. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. J Clin Oncol. 2008 May 10; 26(14):2320-6. PMID: 18467723.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  149. Crippa S, Domínguez I, Rodríguez JR, Razo O, Thayer SP, Ryan DP, Warshaw AL, Fernández-del Castillo C. Quality of life in pancreatic cancer: analysis by stage and treatment. J Gastrointest Surg. 2008 May; 12(5):783-93; discussion 793-4. PMID: 18317851.
    Citations: 19     Fields:    Translation:Humans
  150. Wheatley-Price P, Asomaning K, Reid A, Zhai R, Su L, Zhou W, Zhu A, Ryan DP, Christiani DC, Liu G. Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma. Cancer. 2008 Mar 01; 112(5):1037-42. PMID: 18205184.
    Citations: 22     Fields:    Translation:Humans
  151. Kachnic LA, Hong TS, Ryan DP. Rectal cancer at the crossroads: the dilemma of clinically staged T3, N0, M0 disease. J Clin Oncol. 2008 Jan 20; 26(3):350-1. PMID: 18202407.
    Citations: 7     Fields:    Translation:Humans
  152. Zuckerman DS, Ryan DP. Adjuvant therapy for pancreatic cancer: a review. Cancer. 2008 Jan 15; 112(2):243-9. PMID: 18050292.
    Citations: 20     Fields:    Translation:Humans
  153. Sykes DB, Ting DT, Barbie DA, Chen YB, Deangelo DJ, and Ryan DP. Hematology-Oncology. Ed Mark Sabatine. Pocket Medicine. 2008.
  154. Ryan DP and Mamon H. Management of Locally Advanced Pancreatic Cancer. UpToDate. 2008; www.uptodate.com.
  155. Ryan DP. Adjuvant Therapy for Pancreatic Cancer. UpToDate. 2008; www.uptodate.com.
  156. Ryan DP and Willett CG. Classification and Epidemiology of Anal Cancer. UpToDate. 2008; www.uptodate.com.
  157. Ryan DP. Colon Cancer. Eds Chabner BA, Lynch TJ, and Longo DL. Harrison's Manual of Oncology. 2008.
  158. Ryan DP and Willett CG. Clinical Features, Staging, and Treatment of Anal Cancer. UpToDate. 2008; www.uptodate.com.
  159. Ryan DP. Chemotherapy for Advanced Pancreatic Cancer. UpToDate. 2008; www.uptodate.com.
  160. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007 Oct 20; 25(30):4787-92. PMID: 17947726.
    Citations: 40     Fields:    Translation:Humans
  161. Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007 Aug 01; 110(3):581-9. PMID: 17583545.
    Citations: 67     Fields:    Translation:HumansCTClinical Trials
  162. Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci. 2008 Feb; 53(2):564-70. PMID: 17597402.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  163. Kozak KR, Kachnic LA, Adams J, Crowley EM, Alexander BM, Mamon HJ, Fernandez-Del Castillo C, Ryan DP, DeLaney TF, Hong TS. Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment. Int J Radiat Oncol Biol Phys. 2007 Aug 01; 68(5):1557-66. PMID: 17544599.
    Citations: 8     Fields:    Translation:HumansPHPublic Health
  164. Hezel AF, Ryan DP. Emerging therapies for colorectal cancer. Expert Opin Investig Drugs. 2007 Jun; 16(6):867-76. PMID: 17501698.
    Citations: 2     Fields:    Translation:HumansAnimals
  165. Meyerhardt JA, Stuart K, Fuchs CS, Zhu AX, Earle CC, Bhargava P, Blaszkowsky L, Enzinger P, Mayer RJ, Battu S, Lawrence C, Ryan DP. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol. 2007 Jul; 18(7):1185-9. PMID: 17483115.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  166. Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007 May; 450(5):529-37. PMID: 17372756.
    Citations: 53     Fields:    Translation:HumansCells
  167. Berkenblit A, Eder JP, Ryan DP, Seiden MV, Tatsuta N, Sherman ML, Dahl TA, Dezube BJ, Supko JG. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):584-90. PMID: 17255281.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  168. Meyerhardt JA, Clark JW, Supko JG, Eder JP, Ogino S, Stewart CF, D'Amato F, Dancey J, Enzinger PC, Zhu AX, Ryan DP, Earle CC, Mayer RJ, Michelini A, Kinsella K, Fuchs CS. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2007 Oct; 60(5):661-70. PMID: 17216531.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  169. Ryan DP. Adjuvant Therapy for Pancreatic Cancer. UpToDate. 2007; www.uptodate.com.